Under the terms of the deal, Alchemab and Lilly will work together on up to five new antibodies, according to a Jan. 9 ...

Alchemab Therapeutics, a biopharmaceutical company aiming to identify and develop naturally occurring therapeutic antibodies ...

DNL343 and fosigotifator are made to activate the ISR pathway protein eIF2B, but both failed to slow ALS progression in the HEALEY trial.

About a year ago, Tenvie President and Chief Scientific Officer Tony Estrada approached Denali CEO Ryan Watts and others in ...

Stephen Hawking would have turned 83 years old. Unfortunately, the world-renowned physicist passed away in 2018. Before his ...

The following is a summary of “Education moderates the association between motor involvement and executive status in ALS,” published in the December 2024 issue of Neurology by Aiello et al.

Neurodegenerative diseases pose a serious threat to public health, with an increasing impact among the elderly population.

A University of California, Irvine-led research team has discovered intricate molecular mechanisms driving the RNA processing defects that lead to Huntington's disease and link HD with other ...

A research team has discovered intricate molecular mechanisms driving the RNA processing defects that lead to Huntington's disease and link HD with other neurodegenerative disorders such as ...

Neology Development Group closed on a $63.5 million bridge loan from Barry Sternlicht's Starwood Property Trust to pay off ...

A University of California, Irvine-led research team has discovered intricate molecular mechanisms driving the RNA processing ...

For the primary analysis, a total of 186 participants who received DNL343 treatment were compared to 139 participants who ...